Pharmaceutical industry – Page 23
-
BusinessLandmark China cancer drug full approval ‘first of a wave’
Chi-Med’s fruquintinib is a result of China’s evolving drug innovation and regulation
-
NewsBitter feuding at Cochrane healthcare audit body paralyses organisation
One member has been expelled from the governing board while another four resign with accusations of pharmaceutical industry bias flying
-
BusinessBuilding resilience to climate threats
As extreme weather events become more frequent, chemical and pharmaceutical producers are taking steps to fend them off in future
-
ResearchGenentech antibiotic quells resistance
Modified arylomycin combines high potency with new mechanism of action
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessUS court overturns plant safety rule delay
Appeal finds Trump’s postponement of the 2017 Chemical Disaster Rule was unlawful
-
OpinionFeeding the confusion
When it comes to working out what foods do to our bodies, mostly we just don’t know
-
OpinionBehind enemy lines
When trade war breaks out, globalised industries ship out to dodge tariffs
-
BusinessUS approves first RNA interference drug
Alnylam’s Onpattro (patisiran) can treat a rare hereditary disease by silencing a specific gene
-
BusinessBusinesses use blockchain to take on trustlessness
Big companies are looking to blockchain technology to track transactions, finds Andy Extance, while upstarts exploit its cryptocurrency origins
-
-
BusinessVaccine scandal and heart drug recall show China’s pharma struggles
Fifteen arrests amid evidence of bribery related to vaccines, despite new standards and penalties for fraud
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessTrump coaxes big promises from big pharma
Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse
-
BusinessDrugmaker blocks Nevada execution
Alvogen obtains a restraining order to delay US prisoner’s execution, saying Nevada state obtained its sedative midazolam via ‘subterfuge’
-
BusinessJ&J and the question of shadow research
Former academic researcher who found that talc is not carcinogenic admits that J&J funded his work, but says that fact is immaterial
-
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
NewsFears that US 'right to try' law could put patients at risk
Legislation will give terminally ill patients the option of taking medicines that have had little testing
-
BusinessUS senators launch probe of Novartis’ payments to Trump lawyer
Congress demands info from Novartis about its $1.2m in outflows to Michael Cohen, just as it was negotiating payments for its cancer drug
-
BusinessTrump lays out plan to slash drug costs
White House strategy to reduce pharmaceutical prices faces backlash from the industry, which cautions against the ‘far-reaching’ proposals